This trial is testing a new immunotherapy treatment for renal cell carcinoma. The treatment involves taking dendritic cells from the patient, loading them with RNA from the patient's tumor, and then injecting them back into the patient. The treatment is given in combination with other drugs.
1 Primary · 3 Secondary · Reporting Duration: Through study completion, an average of 2 years
120 Total Participants · 2 Treatment Groups
Primary Treatment: CMN-001 · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: